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Background: We contrasted impacts on all-cause and cardiovascular disease (CVD) mortality of diabetes vs. CVD.
Methods: Among participants the Tehran lipid and glucose study aged ≥ 30 years (n= 9752), we selected those who
participated in the follow-up study until 20 March 2009 (n= 8795). Complete data on covariate were available for 8, 469
participants, contributing to a 67935 person-year follow up. In the analysis of outcomes (all-cause and CVD mortality),
diabetes and CVD were assessed using Cox proportional hazard regression model adjusting for established CVD risk
factors. We used population attributable hazard fraction (PAHF) and rate advancement period (RAP) that expresses how
much sooner a given mortality rate is reached among exposed than among unexposed individuals.
Results: Ten percent of the participants self-reported to have pervious CVD, and diabetes was ascertained in 17% of
participants at baseline examination. During a median follow-up of 9 years 386 participants died of which 184 were due
to CVD. All-cause and CVD mortality rate (95% CIs) were 5.5 (5.0-6.1) and 2.6 (2.3-3.0) per 1000 person-year, respectively.
The PAHF of all-cause mortality for diabetes 9.2 (7.3-11.1) was greater than the one for CVD 3.5 (1.1-5.5). RAP estimates
for all-cause mortality associated with diabetes ranged from 7.4 to 8.6 years whereas the RAP estimates for all-cause
mortality associated with CVD ranged from 3.1 to 4.3 years. The PAHF of CVD mortality for diabetes 9.4 (6.8-12.0) was
greater than the one for CVD 4.5 (1.8-7.0). RAP estimates for CVD mortality associated with diabetes ranged from 8.2 to
9.8 years whereas the RAP estimates for CVD mortality associated with CVD ranged from 4.7 to 6.7 years.
Conclusions: We demonstrated that diabetes, which was shown to be keeping pace with prevalent CVD in terms of
conferring excess risk of incident CVD, is currently causing more deaths in the population than does CVD.
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Mortality is an important measure of population health
and is often used to assign priorities in health interven-
tions [1,2]. Cardiovascular disease (CVD) has long been
known as the leading cause of mortality and morbidity in
developed countries [3]. The recognition and management
of cardiovascular risk factors led to a decline in CVD
related mortality rates in the 1960s. However, the* Correspondence: fzhadaegh@endocrine.ac.ir
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distribution, and reproduction in any mediumincreases in the prevalence of type 2 diabetes mellitus
(hereafter diabetes) and obesity are potential warning
signs that the hard-fought gains in mortality improve-
ments might be arrested or even reversed [4,5]. The
World Health Report 1999 estimates that in 1998, 78% of
the burden of non-communicable diseases and 85% of the
CVD burden arose from the low and middle income
countries [6]. The high burdens of CVD in the develop-
ing countries are attributable to the increasing incidence
of atherosclerotic diseases, perhaps due to urbanization
[7-9]. Diabetes is not only a current common disease but
its prevalence is expected to increase, especially inCentral Ltd. This is an Open Access article distributed under the terms of the
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has been observed to increase the risk of cardiovascular
complications independently of the existing estimated
risk [12].
Diabetes has been shown by some studies to be a
CVD equivalent in contribution to the CVD mortality in
some studies [13-17]. These studies have solely relied on
relative risk, while neglecting the prevalence of the dia-
betes and CVD. Furthermore, diabetes and CVD have
never been weighted against each other with respect to
the all-cause mortality. Routinely reported statistics
based on death certification seriously underestimate
mortality from diabetes. In fact, mortality from diabetes
is underestimated four- to fivefold by methods of ana-
lysis of death certification data which use only under-
lying cause of death [13]. Individuals with diabetes most
often die of cardiovascular and renal disease and not
from a cause uniquely related to diabetes, such as ketoa-
cidosis or hypoglycemia [14]. Therefore, mortality attrib-
utable to diabetes could be expected to be much higher,
since diabetes is a serious and chronic condition. Al-
though some developed countries have documented an
improved survival of persons with diabetes, the
increased prevalence is most likely due to increased inci-
dence rather than improved survival [15].
Population risks of CVD and all-cause mortality due
to diabetes have been previously documented in differ-
ent population [16,17]. It has also been shown that
population-attributable risk fraction should be periodic-
ally recalculated so that we can adequately capture
trends in the population [18]. As the issue is of consider-
able clinical importance, particularly for public health
strategies aimed at reducing mortality, we contrasted the
population-wide impacts on the all-cause and CVD mor-
tality of diabetes vs. CVD. We used population attribut-
able hazard fraction (PAHF) as an epidemiologic tool
which takes into account the prevalence of risk factors
as well as the strength of their associations with mortal-




Detailed descriptions of the Tehran lipid and glucose
study (TLGS) have been reported elsewhere [20,21]; in
brief, the TLGS is a large scale, long term, community-
based prospective study performed on a representative
sample of residents of district No. 13 of Tehran, capital
of Iran. Age and sex distributions of the population in
the district were representative of the overall population
of Tehran at the time of the baseline examination. The
TLGS, has two major components: a cross-sectional
prevalence study of non-communicable disease and
associated risk factors, implemented between March1999 and December 2001, and a prospective follow-up
study. Data collection is ongoing, designed to continue
for at least 20 years, at 3-year intervals. A total of 27 340
residents aged ≥3 years were invited by telephone call, of
which 15, 010 residents participated in first examination
cycle and another 3 ,551 residents were first examined at
the second examination cycle. Participants were categor-
ized into the cohort (n = 10 394) and intervention groups
(n = 8 167), the latter to be educated for implementation
of life style modifications. For the current study, among
participants aged ≥30 years (n = 9 752), we selected those
who participated in the follow-up study until 20 March
2009 (n = 8, 795). Complete data on covariate were avail-
able for 8, 469 participants, contributing to a 67, 935
person-year follow up. At the time of this study, the me-
dian follow up time was 9 years.
Clinical and laboratory measurements
A trained interviewer collected information using a pre-
tested questionnaire. The information obtained included
demographic data, drug history, past medical history of
CVD, hypertension, and diabetes and smoking status [22].
After a 15-minute rest in the sitting position, two mea-
surements of blood pressure were taken, on the right arm,
using a standardized mercury sphygmomanometer (cali-
brated by the Iranian Institute of Standards and Industrial
Researches); the mean of the two measurements was con-
sidered as the participant’s blood pressure.
A blood sample was drawn between 7:00 and 9:00 AM
from all study participants, after 12 to 14 hours over-
night fasting. All the blood analyses were undertaken at
the TLGS research laboratory on the day of blood collec-
tion. Plasma glucose was measured using an enzymatic
colorimetric method with glucose oxidase. Fasting
plasma glucose (FPG) measurement was performed for
all participants, and the standard 2-hour post-challenge
plasma glucose (2 h-PCPG) test for those not on
glucose-lowering drugs. Total cholesterol (TC) was
assayed, using the enzymatic colorimetric method with
cholesterol esterase and cholesterol oxidase. High-
density lipoprotein cholesterol (HDL-C) was measured
after precipitation of the apolipoprotein B containing
lipoproteins with phosphotungistic acid. Analyses were
performed using Pars Azmon kits (Pars Azmon Inc.,
Tehran, Iran) and a Selectra 2 auto-analyzer (Vital Sci-
entific, Spankeren, Netherlands). All samples were ana-
lyzed when internal quality control met the acceptable
criteria. The intra and inter-assay coefficients of vari-
ation were both <2.2% for plasma glucose, and 0.5 and
2% for TC, respectively [20].
Outcome measurements
Details of cardiovascular outcomes have been published
elsewhere [23]. In this ongoing study every TLGS’
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the previous year, by telephone. They are questioned by a
trained nurse regarding any medical conditions or
whether a related event have occurred, a trained physician
collects complementary data during a home visit and/or a
visit to the respective hospital to collect data from the par-
ticipants medical files. In the case of mortality, data are
collected from the hospital or the death certificate by an
authorized local physician. Collected data are evaluated by
an outcome committee consisting of a principal investiga-
tor, an internist, an endocrinologist, a cardiologist, an epi-
demiologist, and the physician who collects the outcome
data. Other experts are invited for evaluation of non-
communicable disorders, as needed. A specific outcome
for each event is assigned according to International Stat-
istical Classification of Diseases and Related Health Pro-
blems criteria, 10th Revision, and American Heart
Association classification for cardiovascular events
[20,24,25]. Coronary heart disease (CHD) includes cases
of definite myocardial infarction (MI) diagnosed by elec-
trocardiogram (ECG) and biomarkers, probable MI (posi-
tive ECG findings plus cardiac symptoms or signs and
biomarkers showing negative or equivocal results), un-
stable angina pectoris (new cardiac symptoms or changing
symptom patterns and positive ECG findings with normal
biomarkers), angiographic proven CHD and CHD death.
CVD is specified as a composite measure of any CHD
events, stroke, or cerebrovascular death.
Definition of terms
Current smoker was defined as a person who smokes
cigarettes daily or occasionally. A previous history of
CVD reflected any prior diagnosis of CVD by a phys-
ician. In accordance with the definition provided by
American Diabetes Association, participants were
classified as having diabetes at the baseline if they met
at least one of these criteria: FPG ≥7 mmol.l-1, or
2 h-PCPG ≥ 11.1 mmol.l-1 or taking anti-diabetic medi-
cation [16].
Statistics analysis
Findings on covariate variables are expressed as means
(SD) or percentages for continuously distributed and
categorical variables, respectively.
In the analysis of outcomes (all-cause and CVD mortal-
ity), diabetes and CVD were assessed using Cox propor-
tional hazard regression model. Survival time was the
time from start of the follow-up period to the date of the
first incident, CVD event or death (failure). The censoring
time of an individual was the time from entry into the
study to loss to follow-up or the end of the study (20th
March 2009), whichever happened first. Censored obser-
vation meant the individuals either refused to participate
further in the study (lost to follow-up), died (from non-CVD causes), when death was not the study outcome
(competing risk) or continued until 20th March 2009
when the study was ended (administrative censoring). Po-
tential confounding effects of age, smoking, systolic blood
pressure, use of anti-hypertensive drugs, lifestyle modifica-
tion intervention, total and HDL cholesterol were
accounted for in the multivariate regression models. We
also examined if direction or magnitude of the association
of diabetes and CVD with different endpoints were modi-
fied by intervention, or each other. As such, the inter-
action term for intervention×diabetes, intervention×CVD,
and diabetes×CVD were introduced into regression mod-
els. The significance of interactions (lack of independence)
was tested by likelihood ratio test.
Wald tests of the linear hypotheses concerning the
Cox regression models coefficients (paired homogeneity
test) were performed to test the null hypotheses that the
hazard ratios (effect size) for diabetes were equal to
those for CVD.
Recently, Chen et al. and Samuelsen et al. have pro-
posed a definition for population–attributable fraction
(PAF) for cohort studies with time-to-event, i.e. Popula-
tion Attributable Hazard Fraction (PAHF). The PAHF is
defined based on the effect of the hypothetical risk factor
modification to the low-risk level; it is estimated at the
instantaneous time point t:
PAHF ¼ h tð Þ  h1 tð Þ
h tð Þ ¼
p tð Þ HR tð Þ  1ð Þ
1þ p tð Þ HR tð Þ  1ð Þ ;
where p is proportion exposed at time t and HR(t) = h2
(t)/h1(t) denotes instantaneous hazard ratio at time t
[26,27]. This measure describes the approximate propor-
tion of events that could be avoided by the risk factor
modification in a short time interval [t, t +Δt], where Δt
! 0. We used proportion exposed at baseline, p= p(0) as
suggested [27,28]. As such the formula corresponds to
the traditional PAF [29] formula as was presented in the
literatures by Levin [19].
Rate advancement period (RAP) has been encouraged
to be used as an effective risk communication tool. It
expresses how much sooner a given mortality rate is
reached among exposed than among unexposed indivi-
duals [30]. RAPs for diabetes and CVD were calculated
in years as suggested by literature [31].
Participants and adjustment for potential selection bias
Baseline age, use of anti-hypertensive drugs, systolic
blood pressure, smoking, diabetes, and history of CVD,
were included in the logistic model with participation as
outcome. The probability of participation was estimated
using logistic model and used as a propensity score. We
added this propensity score to the survival models as a
covariate and examined if the probability of participation
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probability of participation was not associated with any
of the outcomes under the investigation (P values> 0.8)
and the parameter estimates remained essentially un-
changed. Therefore, the selection bias is unlikely to have
affected our estimations.
We set the statistical significance level at a two-tailed
type I error of 0.05. All statistical analyses were per-
formed using STATA version 12 (STATA, College Sta-
tion, Texas USA).
Medical ethics
We certify that all applicable institutional and govern-
mental regulations concerning the ethical use of human
volunteers were followed during this research. Informed
written consent was obtained from all participants and
the Ethical Committee of the Research Institute for
Endocrine Sciences approved this study.
Results
Baseline characteristics of the participants are presented
in Table 1. Mean age of the participants was 33.3 years
(19.0). Ten percent of the participants self-reported to
have pervious CVD, and diabetes was ascertained in 17%
of participants at baseline examination. During a median
follow-up of 9 years 386 participants died of which 184
were due to CVD. All-cause and CVD mortality rate
(95% CIs) were 5.5 (5.0-6.1) and 2.6 (2.3-3.0) per 1000
person-year, respectively.
Among women, effects of diabetes and CVD on all-
cause and CVD mortality were independent of each other.
However, among men diabetes and CVD mutually modi-
fied effects of each other. Therefore, we excluded partici-
pants with both diabetes and CVD; as such we compared
participants with diabetes/without CVD with those with
CVD/without diabetes. Nonetheless, the point estimates
for PAHFs and RAP remained essentially unchanged. To
avoid complexity, thus, we reported results obtained fromTable 1 Characteristics of the participants
Wome
Observations (n) 4 762
Age (year) 33.24 (18
Systolic blood pressure (mmHg) 114.62 (1
Total cholesterol (mmol.l-1) 5.2 (1.2
High-density lipoprotein Cholesterol (mmol.l-1) 1.16 (0.
Antihypertensive drug (users vs. non-users) 978 (0.2
Current Smoking (smokers vs. non-smokers) 185 (0.0
History of cardiovascular disease (yes vs. no) 373 (0
Diabetes (yes vs. no) 631 (0.1
Cardiovascular mortality (per 1000 person-year) 1.5 (1.1-
All-cause mortality (per 1000 person-year) 3.6 (3.1-4original sample assuming that diabetes and CVD inde-
pendently contributed to the all-cause and CVD mortality
(data not shown). The intervention did not contributed to
the incidence of the outcomes under the investigation,
neither did it modify the effects of CVD or diabetes on
the outcomes (P values> 0.2).
Table 2 presents the comparative quantification of
CVD and all-cause mortality attributable to diabetes and
history of previous CVD. The HRs for all-cause mortal-
ity of diabetes was greater than those of CVD. The dif-
ference, however, did not achieve statistical significance
among men. The PAHF of all-cause mortality for dia-
betes 9.2 (7.3-11.1) was greater than the one for CVD
3.5 (1.1-5.5). RAP estimates for all-cause mortality asso-
ciated with diabetes ranged from 7.4 to 8.6 years
whereas the RAP estimates for all-cause mortality asso-
ciated with CVD ranged from 3.1 to 4.3 years.
Tables 3 and 4 presents the comparative quantification
of CVD and all-cause and CVD mortality attributable to
diabetes and history of previous CVD. The HRs for
CVD mortality of diabetes was greater than those of
CVD. The difference, however, did not achieve statistical
significance. The PAHF of CVD mortality for diabetes
9.4 (6.8-12.0) was greater than the one for CVD 4.5 (1.8-
7.0). RAP estimates for CVD mortality associated with
diabetes ranged from 8.2 to 9.8 years whereas the RAP
estimates for CVD mortality associated with CVD ran-
ged from 4.7 to 6.7 years.
Discussion
Using data from a well-characterized prospective cohort
study of men and women, we comparatively quantified
the population-wide burden of all-cause and CVD mor-
tality attributable to diabetes and CVD. We observed
that population mortality conferred by diabetes is not
lower than those conferred by previous CVD events. In
fact, among women population mortality from any cause
conferred by diabetes was significantly higher than thosen Men Total
4 033 8 795
.23) 33.34 (19.97) 33.29 (19.01)
9.41) 115.88 (18.32) 115.17 (18.95)
6) 4.95 (1.13) 5.09 (1.21)
28) 1.04 (0.26) 1.11 (0.28)
1) 466 (0.12) 1 444 (0.16)
4) 1 151 (0.30) 1 336 (0.15)
.9) 542 (0.11) 915 (0.10)
6) 818 (0.18) 1 449 (0.17)
1.9) 4.0 (3.4-4.8) 2.6 (2.3-3.0)
03) 7.8 (6.9-8.8) 5.5 (5.0-6.1)
Table 2 Effects of diabetes and history of cardiovascular disease on mortality from all-cause or cardiovascular disease
Female Male Total
HR (95% CIs) P value HR (95% CIs) P value HR (95% CIs) P value
All-cause mortality
History of cardiovascular disease 1.47 (0.98-2.20) 0.061 1.47 (1.03-2.11) 0.034 1.48 (1.15-1.91) 0.002
Diabetes 2.66 (1.83-3.85) 0.000 1.81 (1.33-2.46) 0.000 2.06 (1.65-2.57) 0.000
Cardiovascular mortality
History of cardiovascular disease 1.62 (0.92-2.87) 0.096 1.70 (1.08-2.68) 0.022 1.61 (1.13-2.29) 0.008
Diabetes 2.76 (1.58-4.80) 0.000 1.93 (1.28-2.90) 0.002 2.17 (1.57-3.01) 0.000
Models were adjusted for age, sex (were not sex-specific), current smoking, systolic blood pressure, using antihypertensive drugs, total and high-density
lipoprotein cholesterol.
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cept of RAP that provides an excellent translation into
lay language. Accordingly, we observed that diabetic
patients died 7–10 years sooner than did those withoutTable 3 Comparing burden of all-cause mortality due to
diabetes with those due to CVD
Diabetes History of CVD
Women
Prevalence (%) 17.7 11.4
HR1 (95%CIs) 2.66 (1.83-3.85) 1.47 (0.98-2.20)
Wald χ2 4.65 (P for paired
homogeneity test2 = 0.031 )
PAHF3 (95%CIs) 11.0 (8.4-13.5) 3.7 (0.0-7.3)
RAP4 (years) 8.6 3.1
Men
Prevalence (%) 16.3 9.3
HR1 (95%CIs) 1.81 (1.33-2.46) 1.47 (1.03-2.11)
Wald χ2 1.19 (P for paired
homogeneity test2 = 0.275 )
PAHF3 (95%CIs) 7.9 (5.3-10.5) 3.0 (0.01-5.7)
RAP4 (years) 7.4 4.3
Total
Prevalence (%) 17.1 10.4
HR1 (95%CIs) 2.06 (1.65-2.57) 1.48 (1.15-1.91)
Wald χ2 5.26 (P for paired
homogeneity test2 = 0.022 )
PAHF3 (95%CIs) 9.2 (7.3-11.1) 3.3 (1.1-5.5)
RAP4 (years) 8.0 3.5
CVD, cardiovascular disease; HR, hazard ratio; PAHF, population-attributable
hazard fraction; RAP, rate advancement period.
1. HRs and their 95% CIs were estimated by implementing the survival
proportional hazard (Cox) regression analysis.
2. Wald tests of the linear hypotheses concerning the Cox survival regression
models coefficients (paired homogeneity test) were performed to test the null
hypotheses that the hazard ratios (effect size) for prevalent diabetes were
equal to those for prevalent CVD [32].
PAHF ¼ h tð Þh1 tð Þh tð Þ ¼ p tð Þ HR tð Þ1ð Þ1þp tð Þ HR tð Þ1ð Þ ; where p(t) is the proportion exposed to
hypertension at time t. We used proportion exposed at baseline, p= p(0).
4. RAP expresses how much sooner a given mortality rate is reached among
exposed than among unexposed individuals [30].diabetes and that patients with previous CVD died 3–
7 years sooner than did those without CVD.
The PAHF, which incorporates both risk factor preva-
lence and its predictive value (i.e. relative or excess risk),
provide a measure of effectiveness that can be broadly
helpful in deciding which risk factor should be targeted
by health interventions [7]. Our finding shows that mor-
tality could be reduced twice as much by elimination
from the population of diabetes as by elimination from
the population of CVD.
Beverly Levine [33] argued that the most illuminating
questions about the attributable fraction are: What inter-
ventions are available to cause the assumed reduction in
risk among the exposed and the consequent estimated
reduction in disease burden? What proportion of disease
risk could be eliminated if the absolute risk in the
exposed were to suddenly and sustainably go to the level
of absolute risk in the unexposed, while nothing else, in-
cluding absolute risk in the unexposed, were to change?
While there is no doubt that diabetes harbors a causal
effect on CVD [34-38] and all-cause mortality
[36,39,40], whether these effects are exerted through
hyperglycemia or whether it is just an innocent by-
stander has been increasingly challenged [41-43]. Overt
diabetes has been shown to modify the effect on mortal-
ity of hyperglycemia [44]. Insulin resistance another fea-
ture of diabetes, has been shown to increase the risk of
new CVD events [45]. It has been shown that glucose-
related risks do exist before levels currently used to de-
fine diabetes are reached [46,47]. Intensive glucose low-
ering has long been known to decrease microvascular
complications of diabetes. The ADVANCE study (Action
in Diabetes and Vascular Disease: Preterax and Diami-
cron Modified Release Controlled Evaluation) has
sprinkled some hope that intensive glucose control may
confer some benefit on CVD [2]. In the Action to Con-
trol Cardiovascular Risk in Diabetes (ACCORD) study
increased mortality has been attributed to failing to
achieve targets [48]. Traditionally, intensive glucose low-
ering was not achieved without hypoglycemia [8], weight
gain [49], and increased cardiovascular risk (as a side
Table 4 Comparing burden of CVD mortality due to
diabetes with those due to CVD
Diabetes History of CVD
Women
Prevalence (%) 13.9 8.7
HR1 (95%CIs) 2.76 (1.58-4.80) 1.62 (0.92-2.87)
Wald χ2 1.69 (P for paired
homogeneity test2 = 0.194 )
PAHF3 (95%CIs) 11.5 (7.8-15.0) 4.9 (0.3-9.4)
RAP4 (years) 9.8 4.7
Men
Prevalence (%) 14.1 6.7
HR1 (95%CIs) 1.92 (1.28-2.90) 1.70 (1.08-2.68)
Wald χ2 0.14 (P for paired
homogeneity test2 = 0.711 )
PAHF3 (95%CIs) 8.0 (4.4-11.5) 4.3 (1.5-7.1)
RAP4 (years) 8.2 6.7
Total
Prevalence (%) 13.5 6.4
HR1 (95%CIs) 2.17 (1.57-3.01) 1.61 (1.13-2.29)
Wald χ2 1.38 (P for paired
homogeneity test2 = 0.239 )
PAHF3 (95%CIs) 9.4 (6.8-12.0) 4.5 (1.8-7.0)
RAP4 (years) 9.0 5.5
CVD, cardiovascular disease; HR, hazard ratio; PAHF, population-attributable
hazard fraction; RAP, rate advancement period.
1. HRs and their 95% CIs were estimated by implementing the survival
proportional hazard (Cox) regression analysis.
2. Wald tests of the linear hypotheses concerning the Cox survival regression
models coefficients (paired homogeneity test) were performed to test the null
hypotheses that the hazard ratios (effect size) for prevalent diabetes were
equal to those for prevalent CVD [32].
PAHF ¼ h tð Þh1 tð Þh tð Þ ¼ p tð Þ HR tð Þ1ð Þ1þp tð Þ HR tð Þ1ð Þ ; where p(t) is the proportion exposed to
hypertension at time t. We used proportion exposed at baseline, p= p(0).
4. RAP expresses how much sooner a given mortality rate is reached among
exposed than among unexposed individuals [30].
Bozorgmanesh et al. Cardiovascular Diabetology 2012, 11:69 Page 6 of 9
http://www.cardiab.com/content/11/1/69effect of glucose lowering agents ) [2]. It was therefore
associated with an increased CVD and all-mortality [4].
Recently, however, there has been an ever-expanding
body of evidences on the effectiveness of new
approaches to intensify glucose control. New approaches
have been shown to reverse diabetes [50], have lower
risk of hypoglycemia [51], promote weight loss, and
confer decreased CVD risk among diabetic patients.
Findings of the current study can, in a population-wide
scale, determine the potential borders of the achieve-
ment for novel approaches to treat diabetes. Novel ther-
apies can help reduce glucose levels much safer to
much lower levels (which would be concomitant reduc-
tion in mortality from microvascular complications)
meanwhile diabetes-specific modification of atheroscler-
osis may reduce CVD mortality among diabetic patients.
Therefore novel glucose lowering agent may confer apotential for decrease in all-cause mortality. Further-
more, type 2 diabetes has been shown to be prevented
or the onset delayed by lifestyle modification, which al-
though involves costs, imposes no harms [52,53].
We are aware that diabetes and CVD are correlated
and their effects on outcomes are not mutually exclusive
but rather mutually modifiable. Nonetheless, the likeli-
hood ratio test revealed no evidence of significant dia-
betes ×CVD interaction among women. Among men,
where interactions were statistically significant, we
excluded data on participants with both diabetes and
CVD. This subgroup analysis allowed us to directly com-
pare men who had diabetes/without CVD with those
who had CVD/without diabetes. We observed that rela-
tive importance of the two conditions remained un-
changed; our interpretation is, thus, unlikely to have
been considerably affected by the effect-modification.
Furthermore, allowing for the CVD-modified effects of
diabetes simply mean to calculate PAHFs for individuals
with diabetes who also had CVD. While it could be the-
oretically appealing, practically, it is not currently
recommended to intensify glucose control among dia-
betic patients with established macrovascular complica-
tion in order to prevent cardiovascular disease [54]. New
pharmacologic approaches are on the horizon that offer
some hope, though [55].
The clinical implications of the findings reported
herein lies in its observable practical consequences. Dia-
betic patients have residual risk or CVD mortality even
after treatment of established CVD risk factors like
blood pressure and lipid levels [56]. Approval of
glucose-lowering agents may no longer be prudent un-
less they offer additional beneficial impact on CVD or
mortality. Such therapeutic approaches in the light of
the current findings will have much potential to improve
the population longevity. We await more clinical trials
to see if such therapeutic approaches live up to our
expectations. The findings of the current study have
some public health implications as it allows clinicians
more effectively communicate the diabetes-associated
risk their patients. For example, a RAP of 8.6 years can
be used to explain to a 50-year-old diabetic woman that
she has the same risk of death as does a 59-year-old
non-diabetic woman.
Study strengths and limitations
Strength
Strength of the present study lies in its prospective na-
ture, the use of a large population-based-cohort of both
sexes, accurate and valid data on risk factors at baseline,
continuous surveillance of mortality and CVD events
based on standard criteria. We used standard methods
for measurement of plasma glucose including 2-PCPG.
The fact that we adjusted for established CVD risk
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esterol, cigarette smoking, and use of antihypertensive
drugs) makes it unlikely that the strong associations of
the all-cause or CVD mortality to diabetes observed here
are due to confounding with known risk factors, al-
though in an observational study that possibility can
never be definitely excluded. The practical usefulness of
RAP in terms of risk communication still waits thorough
evaluation. However, its simple calculation and intuitive
appeal should make it a worthwhile endeavor [31].Limitations
Some limitations to our study merit mentioning.
1. The number of incident events precluded
stratification of analyses by age.
2. Our findings may not apply to individuals of
different racial and socioeconomic groups than
those in the TLGS population (entirely Persian
middle class).
3. We do not have sufficient data to accurately assess
the relations of various cause-specific deaths to
diabetes. Using aggregate clinical outcome could
have potentially attenuated the strength of the
associations.
4. Some participants might have developed diabetes or
non-fatal CVD during follow up. This
misclassification renders our results to regression
dilution. Regression dilution, however, biases the
estimates towards the null and, thus, is unlikely to
have significant affected the results obtained and the
interpretations inferred herein.
5. Finally, we only considered glycemic status once
intra-individual variability in these measures may
have misclassified participants, but this problem
would produce an underestimate of the effects of
glycemia on outcomes.Conclusions
We have comparatively quantified the public health im-
pact of diabetes and history of previous CVD in terms of
all-cause and CVD mortality. We demonstrated that dia-
betes, which was shown to be keeping pace with previ-
ous CVD events in terms of conferring excess risk of
incident future CVD events, is currently causing more
deaths in the population than do previous CVD eventsAbbreviations
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